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Objective: Whether sucralose, the most commonly used non-nutritive sweetener (NNS), 
affects glucose metabolism in people is unclear. It has been reported that, when 
consumed acutely before an oral glucose tolerance test (OGTT), sucralose enhances 
insulinemic responses and decreases insulin sensitivity in subjects with obesity who are 
not regular consumers of NNS. However, studies in normal-weight adults, none of which 
control for use of NNS, found sucralose does not affect insulin responses to the 
ingestion of glucose or other carbohydrates. The objectives of the current study are to 
determine if those effects of sucralose can be replicated in subjects with obesity, are 
generalizable to normal-weight subjects when controlling for history of NNS use, and 
are caused merely by the sweet taste of sucralose (i.e., sham-feeding). In addition, with 
the aim of identifying potential mechanisms by which sucralose may decrease 
postprandial insulin sensitivity, we here investigated whole-body glucose kinetics by 
using a dual-tracer approach. Finally, we tested the hypothesis that, due to the 
compromised intestinal permeability associated with obesity, sucralose consumption is 
associated with higher plasma sucralose concentrations in people with obesity.  
Research Design and Methods: Ten normal-weight subjects (BMI: 22.8 ± 0.9 kg/m2) and 
nine subjects with obesity (BMI: 37.7 ± 6.1 kg/m2), all non-regular users of NNS, non-
diabetic, and without significant insulin resistance (based on a homeostatic model 
assessment of insulin resistance score < 3), underwent a 5-hour modified OGTT in 
which ingested glucose was labeled with one tracer while a second glucose tracer was 
infused intravenously at a constant rate on three separate testing days. Each testing 
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day differed only by which pre-load solution (water ingestion (control condition), 
sucralose ingestion (experimental condition), or sucralose sham-fed (taste condition)) 
was administered 10 minutes prior to the OGTT in a randomized crossover design. 
Blood samples were taken throughout observation to determine plasma glucose, insulin, 
C-peptide, glucose-dependent insulinotropic polypeptide (GIP), glucose tracer-to-tracee 
ratio, and sucralose concentrations. 
Results: In subjects with obesity, compared to the control condition, sucralose sham-
feeding reduced insulin and C-peptide concentrations within the first hour of the OGTT 
(both p-values ≤ 0.05), whereas sucralose ingestion increased plasma C-peptide 
incremental area under the curve (iAUC) by 22 ± 10% (p < 0.05) and tended to increase 
plasma insulin iAUC by 16 ± 9% (p = 0.09) and plasma glucose iAUC by 34 ± 12% (p = 
0.06). No condition affected GIP. There were no differences among conditions in the 
degree of suppression of endogenous glucose production (EGP) after the glucose load, 
but both sucralose conditions affected the pattern of oral glucose rate of appearance 
(Ra) and glucose rate of disappearance (Rd). Compared to the water condition, 
sucralose affected the pattern of change with time including i) a greater decline (50-60 
min) and subsequently a reduced decline (120-140 min) in oral glucose Ra (p = 0.03), 
and ii) a reduced glucose Rd (50-80 min) and subsequently an increased glucose Rd 
(140-160 min) after the glucose load (p < 0.05). While the reduction in glucose Rd 
during the taste condition and the increase in Rd 140-160 min after the glucose load 
could be explained by prevailing plasma insulin concentrations, the reduction in glucose 
Rd 50-80 min after the glucose load on the experimental condition cannot. During this 
time period, plasma insulin concentrations after sucralose ingestion were similar or 
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higher than after water ingestion, which is in agreement with previous results of a 
decreased insulin sensitivity in subjects with obesity when sucralose ingestion preceded 
an OGTT.  In normal-weight subjects, there were no significant differences among 
conditions in plasma glucose, C-peptide, GIP, or plasma glucose or hormones iAUCs, 
but both sucralose conditions tended to equally lower mean plasma insulin 
concentrations following the OGTT (p = 0.09) and suppressed EGP to a greater degree 
(p = 0.09) compared to water.  There were no significant differences between groups for 
peak sucralose concentrations, the time to reach peak sucralose concentration, and 
plasma sucralose iAUCs (all p-values > 0.19). 
Conclusions: These data demonstrate that sucralose differentially affects hormonal 
responses to an oral glucose load in subjects with obesity and normal weight subjects. 
Sucralose ingestion (not merely its taste) increases insulin secretion to an oral glucose 
load and transiently reduces glucose Rd in people with obesity, but not in normal-weight 
subjects. These findings support the hypothesis that sucralose may have adverse 
effects on glucose metabolism in people with obesity, which is the group that most 
frequently consumes NNS to facilitate weight management. These data also underscore 
a physiological role for sweetness perception in glucose homeostasis, which supports 
the notion that sweetness, regardless of an associated caloric contribution, should be 






 I would like to thank all of those from the university who have helped in some 
way during my time as a graduate student. Dr. Yanina Pepino, my advisor, who 
accepted me into her lab and provided me the opportunity to work on this project. Dr. 
Ruopeng An, who supported my idea for a review paper on non-nutritive sweeteners 
and helped in every step of the way towards achieving my first first-author publication. 
Dr. Alexander Lipka, who has helped me become much more skilled at statistics and 
offered me a teaching assistantship for his statistics course. My committee members, 
Dr. Megan Dailey and Dr. John Erdman, for their suggestions regarding my research 
and guidance in choosing classes.  
 Thank you to all of my lab mates: Raul, Katie, Belen, and Ramiro, for helping me 
whenever I needed it, providing valuable feedback, and creating an enjoyable 
environment to work in. Thank you to Maxwell Holle, who showed me what it takes to be 
a successful graduate student and worked alongside me the entire way towards 
publishing our review paper together. Thank you to Adam Kriska, who shared his 
experiences in graduate school with me and urged me to make decisions with my own 
self-interest in mind. 
 Thank you to all of my friends back home, whose friendship has never dwindled 
despite the distance. It means so much to me to pick up right where we left off every 
time I see any of you. 
vi 
 
 Thank you to my family, especially my parents and grandmother, who have 
supported and encouraged me throughout this process. I would not be here today if not 
for you all. 
 And finally, thank you to my girlfriend Layla Alazawy, who is my partner 
throughout life and who has been with me every step of the way. Your support means 













































TABLE OF CONTENTS 
 
ABBREVIATIONS .................................................................................................... ix 
CHAPTER 1: INTRODUCTION ...............................................................................1 
CHAPTER 2: LITERATURE REVIEW OF SUCRALOSE .......................................5 
CHAPTER 3: RESEARCH DESIGN AND METHODS ..........................................26 
CHAPTER 4: RESULTS .........................................................................................33 
CHAPTER 5: DISCUSSION ...................................................................................44 

















NNS – non-nutritive sweetener(s) 
BMI – body mass index 
AUC – area under the curve 
iAUC – incremental area under the curve 
GLP-1 – glucagon-like peptide 1 
GIP – glucose-dependent insulinotropic peptide 
SGLT1 - sodium-dependent glucose co-transporter isoform 1 
ADME - absorption, distribution, metabolism, and excretion 
OGTT – oral glucose tolerance test 
ADI – acceptable daily intake 
FDA – United States Food and Drug Administration 
PYY – peptide tyrosine tyrosine 
3-OMG – 3-O-methyl glucose 
TIM – tagatose/isomalt mixture 
Ace-K – acesulfame potassium 
HOMA-IR – homeostatic model assessment for insulin resistance 
Total Ra – total rate of glucose appearance 
Oral Ra – oral rate of glucose appearance 
EGP – rate of endogenous glucose production 
Rd – rate of glucose disappearance
1 
 
CHAPTER 1: INTRODUCTION 
 
A hypercaloric diet potentiated by excess sugar consumption is known to 
increase risk of obesity, cardiovascular disease, and type 2 diabetes (Rippe and 
Angelopoulos, 2016a, Rippe and Angelopoulos, 2016b). Therefore, limiting sugar 
consumption, specifically added sugar, is recommended by governmental and health 
organizations around the world (Hess et al., 2012). However, humans have an innate 
attraction towards sweet taste (Steiner, 1974), which makes avoiding sweet-tasting 
foods difficult. Non-nutritive sweeteners (NNS), which are sugar substitutes, provide 
intense sweet taste without the addition of sugar or calories. Therefore, NNS use is 
growing in popularity, with about 25% of children and 41% of adults reportedly 
consuming them (Sylvetsky et al., 2017). 
Despite their negligible caloric contribution, data from animal models and human 
cell lines suggest that NNS are not metabolically inert. The sweet taste receptor, 
T1R2+T1R3, is a heterodimer that detects sugars and NNS and is expressed in many 
tissues beyond the oral cavity (Laffitte et al., 2014). In the intestine, activation of these 
sweet taste receptors by sugars results in the secretion of the incretins glucagon-like 
peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) from 
enteroendocrine L-cells and K-cells, respectively (Jang et al., 2007, Kojima and 
Nakagawa, 2011). Activation of these receptors also increases active glucose 
absorption through upregulation of sodium-dependent glucose co-transporter isoform 1 
(SGLT1) (Margolskee et al., 2007, Moran et al., 2010, Stearns et al., 2010) and passive 
glucose absorption through increased translocation of GLUT2 to the intestinal lumen 
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(Mace et al., 2007). In the pancreas, activation of sweet taste receptors expressed in 
beta-cells mediates insulin secretion (Kojima et al., 2015, Kyriazis et al., 2012, Malaisse 
et al., 1998, Nakagawa et al., 2009). 
Additionally, it has been reported that sucralose, one of the most widely used 
NNS, stimulates the secretion of incretins in cell lines (Jang et al., 2007, Margolskee et 
al., 2007), indicating that sucralose is capable of interacting with the sweet taste 
receptors located beyond the oral cavity. The above findings have raised the question of 
whether sucralose consumption may affect glucose absorption and alter the glycemic 
response to a caloric load in humans. Numerous studies have been conducted 
investigating the post-ingestive effects of sucralose in human and animal models. 
Presented hereafter will be a comprehensive review of all of the current literature 
related to the absorption, distribution, metabolism, and excretion (ADME) of sucralose 
and its effect on fasting and postprandial glycemic control in both chronic and acute 
studies. Included in this review is a study conducted by Pepino and collaborators 
(Pepino et al., 2013), which was the first to examine the effects of sucralose consumed 
prior to a glucose load strictly in people with obesity who were not regular consumers of 
NNS (review in detail later). They found that the acute ingestion of sucralose prior to an 
oral glucose tolerance test (OGTT) enhanced insulinemic responses. However, in 
contrast with such findings in people with obesity, data from most studies conducted in 
healthy, normal-weight people show that sucralose does not affect glycemic or 
insulinemic responses to the ingestion of a carbohydrate load (Brown et al., 2011, Wu et 
al., 2013, Wu et al., 2011). The reason(s) for the discrepancy between the results from 
these studies and Pepino and collaborators data is not clear, but we hypothesize it is 
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related to sucralose having differential effects in subjects with obesity and normal-
weight subjects. 
The primary goals of our present study were to evaluate the acute effects of 
sucralose ingestion, versus merely perceiving the sweet taste of sucralose in the mouth, 
on hormonal responses to an OGTT and whole-body glucose metabolism in people with 
obesity and in normal-weight people. We hypothesized that the ingestion of sucralose 
before a glucose load, but not the mere perception of its sweet taste, would cause an 
increase in glucose-stimulated insulin secretion, a reduced suppression in endogenous 
glucose production, and a reduced glucose rate of disappearance in subjects with 
obesity, but would have no effects in normal-weight subjects. Accordingly, we assessed 
effects of acute sucralose ingestion versus water ingestion or sucralose sham-fed (i.e., 
tasted without being swallowed) on plasma glucose, glucose kinetics, and hormonal 
responses to a glucose load. In addition, we hypothesized that people with obesity were 
more vulnerable to the metabolic effects of sucralose than their normal-weight peers 
because, due to the compromised intestinal permeability associated with obesity 
(Gummesson et al., 2011), sucralose consumption would result in higher peak 
sucralose concentrations in plasma in people with obesity. 
For our study, we selected sucralose because 1) it is one of the eight (sucralose, 
saccharin, aspartame, acesulfame-K, neotame, advantame, stevia, and luo han guo 
fruit extract) NNS currently approved for use by the US FDA; 2) of the eight NNS, it is 
the most commonly used and found in the most food products (Yang 2010); and 3) it is 
the NNS used in Pepino and collaborators’ previous study (Pepino, Tiemann et al. 
2013), where it was demonstrated that sucralose alters glycemic and hormonal 
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responses to an OGTT in subjects with obesity. In the following chapter, I present a 
detailed review on sucralose, including its chemistry, sensory properties, 
pharmacokinetic profile, and metabolic effects both in pre-clinical and clinical studies. 
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CHAPTER 2: LITERATURE REVIEW OF SUCRALOSE 
 
2.1 Chemistry, Sensory Properties, and Nutritional Value of Sucralose 
 Sucralose is artificially derived from the disaccharide sucrose by substituting 
three hydroxyl groups with chlorine. These subtle changes keep sucralose structurally 
similar to sucrose, and maintain its high water solubility (Jenner and Smithson, 1989). 
However, the substitution with chlorine causes the conformation of the sucralose 
molecule to be oriented in such a way that glycosidic enzymes are unable to digest 
sucralose into monosaccharides, thus becoming unable to undergo metabolism 
(Magnuson et al., 2016). As will be later discussed, most sucralose leaves the body 
intact and unchanged (Roberts et al., 2000). 
 Sucralose stimulates the human sweet taste receptor by binding to its Venus Fly 
Trap domain located on the N-terminal domain (Liu et al., 2011, Masuda et al., 2012). In 
determining the binding location of sucralose to the sweet taste receptor, Masuda et al. 
were unable to identify the binding location of sucrose because of the faint cellular 
responses compared to sucralose and other artificial sweeteners (Masuda et al., 2012). 
This supports sensory data indicating that the chlorine substitutions make sucralose 
about 400-700 times sweeter than sucrose on a weight for weight basis (Wiet and 
Beyts, 1992). This means that the addition of very small amounts, relative to sucrose, 
are necessary to achieve similar intensities of sweetness. 
 The combination of the potent sweet taste along with the inability to provide a 
caloric value make sucralose an appealing replacement for sugar. Sucralose is the most 
commonly used NNS today, an ingredient in over 1,500 food products (Yang, 2010), 
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and is most commonly known for sweetening Splenda. Because of its widespread use, 
investigations into this sweetener are important to identify its efficacy as a substitute for 
sugar. 
2.2 Sucralose Acceptable Daily Intake and Estimating Average Intake 
 The acceptable daily intake (ADI) is an estimate of the amount of a substance, 
on a per body weight basis, that can be ingested daily over a lifetime without 
appreciable risk. The FDA and Joint FAO/WHO Expert Committee on Food Additives 
have set the ADI for sucralose at 5 mg/kg of body weight (FDA, 2018) and 15 mg/kg of 
body weight (JECFA, 1991), respectively. These values are important to reference 
when determining how high of a dose is considered safe when given in a study. 
However, it is also crucial to know if consumers of sucralose are within these ranges, 
and if they are, where the low, average, and high users fall within this range. When 
conducting a study, administering amounts that are typically consumed can give results 
that better reflect an outcome representative of the population. Hereafter, all references 
to the ADI will be to the amount set by the FDA. 
 An overview of 11 studies, which estimated NNS intake in various countries and 
age groups mainly using food diaries and 24-hour dietary recalls, has compiled the 
results and estimated that the average user only consumes 3% to 9% of the ADI (0.15-
0.45 mg/kg) and high users consume 18% to 45% of the ADI (0.9-2.25 mg/kg) 
(Renwick, 2006). The highest reported consumption in these 11 studies was 2.25 
mg/kg/day, which is less than half of the ADI (FSANZ, 2004). 
 Several more studies have been conducted to estimate the average intake since 
the work of Renwick 2006. In Belgium, 24-hour recalls were completed by 3083 
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participants over 15 years of age, which determined that the highest users (95th 
percentile) consumed 1.53 mg/kg/day (30% of the ADI) (Huvaere et al., 2012). Another 
study in Belgium, which used a more conservative approach to estimating daily 
sucralose intake, estimated that the average user consumed 0.8 mg/kg/day (16% of the 
ADI) and high users consumed 3.1 mg/kg/day (62% of the ADI) (Van Loco et al., 2015). 
In Korea, 24-hour recalls were completed by 8081 participants aged 1-65 years old (Ha 
et al., 2013). Two estimates were made based on the assumption of randomly choosing 
foods with and without sweeteners, or deliberately choosing foods sweetened with 
sucralose. The randomly chosen estimate came out to 1.2 mg/kg/day (24% of the ADI) 
and 3.4 mg/kg/day (68% of the ADI) for average and high users, respectively. The 
deliberately chosen estimate came out to 6.5 mg/kg/day (130% of the ADI) and 17.7 
mg/kg/day (354% of the ADI) for the average and high users, respectively. The 
deliberately chosen estimate is much greater because it is a worst-case scenario, and 
most of the estimate comes from the assumption that soju, an alcoholic beverage in 
Korea sweetened with sucralose, is consumed frequently. 
2.3 Absorption, Distribution, Metabolism, Excretion (ADME) of Sucralose 
2.3.1 Animal Models 
ADME studies of sucralose have been conducted in mice (John et al., 2000a), 
rats (Sims et al., 2000), dogs (Wood et al., 2000), and rabbits (John et al., 2000b), 
which all show that most of the sucralose is recovered unchanged, and that a majority 
of it is excreted in the feces, with a smaller percentage being absorbed and excreted 




2.3.1.1  Mice 
Sixteen mice were divided into 3 treatment groups receiving 100 mg/kg (4 male, 
4 female), 1500 mg/kg (2 male, 2 female), and 3000 mg/kg (2 male, 2 female) of 
sucralose during a single oral gavage administration (John et al., 2000a). A fourth group 
also received a 20 mg/kg IV dose of isotopically labelled 14C-sucralose into their tail 
vein. Urine and feces samples were taken for the next 5 days to record the amount of 
sucralose excreted. The group receiving the dose in their tail vein excreted 80% of the 
sucralose in their urine, 22% in their feces, and 2% was found in their cage debris, for a 
total recovery of 104%. The group receiving 100 mg/kg by oral gavage excreted 23% of 
the dose in the urine, 70% in the feces, and 3% was found in the cage debris, for a total 
recovery of 96%. Comparing the amount of sucralose excreted in the urine, when the 
dose was orally administered, to that of an IV dose, the researchers estimated that 
about 29% of the dose was absorbed in the oral gavage group. The groups receiving 
1500 and 3000 mg/kg in a single oral gavage had similar results to each other, with 15 
and 16% excreted in the urine, 74 and 72% excreted in the feces, and 3 and 5% found 
in the cages, for a total recovery of 92 and 94%, respectively. It is estimated that these 
groups absorbed around 20% of the dose each. Nearly all of the sucralose recovered 
was unchanged, with about 2% of other metabolites found, but there was so little that 
they could not be identified. 
2.3.1.2 Rats 
Three acute studies have been conducted in regards to oral gavage 
administration of sucralose in rats (Sims et al., 2000). Twelve adult rats were divided 
into 2 treatment groups receiving 100 mg/kg (3 male, 3 female) and 1000 mg/kg (3 
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male, 3 female) of sucralose and isotopically labelled [36Cl]sucralose through oral 
gavage. Additionally, four adult rats with their bile ducts cannulated were divided into 2 
groups receiving 50 mg/kg (1 male, 1 female) and 100 mg/kg (1 male, 1 female) of 
sucralose and isotopically labelled [36Cl]sucralose through oral gavage. In the third 
acute study, six rats aged 3 months received 10 mg/kg of sucralose and isotopically 
labelled 14C-sucralose through oral gavage. The researchers found that the group 
receiving 100 mg/kg excreted 8.5% of the dose in urine and 88% in the feces, for a total 
recovery of 96.5%; the group receiving 1000 mg/kg excreted 5% of the dose in urine 
and 90% in the feces, for a total recovery of 95%; and the group receiving 10 mg/kg 
excreted 5% of the dose in urine and 93% in the feces, for a total recovery of 98%. The 
groups that had their bile ducts cannulated excreted 6% and 1.5% of the doses through 
the bile at 50 mg/kg and 100 mg/kg, respectively. The researchers declared that these 
amounts are similar to those found in urine, thus the urinary excretion underestimates 
the total amount of sucralose absorbed by the intestinal tract in rats. About 91% of the 
recovered sucralose in the urine was unchanged, with two more polar conjugates found, 
but unidentified. As nearly 100% of the sucralose found in the feces was unchanged, 
the two conjugates made up less than 1% of the total recovered dose. 
Thirty four adult rats were divided into two groups receiving either a control diet 
(8 male, 8 female) or the same diet containing 3% sucralose (9 male, 9 female) for 26, 
52, or 85 weeks (Sims et al., 2000). At 26, 52, and 85 weeks, rats from both groups 
were given an acute dose of 100 mg/kg 14C-sucralose through oral gavage. The group 
receiving the control diet excreted 7.7% of the dose in the urine and 83.5% in the feces, 
for a total recovery of 91.2% over all 3 of the time points measured. The group receiving 
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the diet with sucralose excreted 6.6% in the urine and 83.9% in the feces, for a total 
recovery of 83.9% over all 3 of the time points measured. The researchers determined 
that there were no differences in percentages of the dose eliminated in the urine and 
feces between the groups receiving the two diets. The recovered sucralose was 
primarily unchanged, with about 10% of similar conjugates found in the urine in the 
acute studies mentioned above. Again, because the feces was nearly 100% unchanged 
sucralose, the conjugates made up less than 1% of the total dose administered. 
2.3.1.3 Dogs 
Two male and two female beagle dogs were administered 10 mg/kg sucralose 
containing 14C-sucralose through a single oral gavage (Wood et al., 2000). After 5 days, 
27.6% of the dose was excreted in the urine, 68.4% in the feces, and 1.6% in the cage, 
for a total recovery of 97.6%. Comparing the urinary excretion of a sucralose dose given 
by oral gavage to that of an IV dose, which is considered to 100% absorption, the 
researchers determined that about 35% of the oral gavage dose was absorbed in the 
gastrointestinal tract. After the 5 day period, small amounts of radioactivity was still 
detectable in the plasma, indicating that it may take more than 5 days for all of orally 
administered sucralose to be excreted. A more polar, glucuronic acid conjugate of 
sucralose was found in the urine, which accounted for about 2-8% of the total oral dose. 
2.3.1.4 Rabbits 
Three pregnant and three non-pregnant rabbits received single oral gavage 
doses of 10 mg/kg of sucralose that included 14C-sucralose (John et al., 2000b). After 5 
days, the pregnant group excreted 21.5% of the dose in urine, 65.2% in the feces, and 
0.4% in the cage, for a total recovery of 87%. The non-pregnant group had similar 
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results, with 22.3% excreted in the urine, 54.7% in the feces, and 3.4% in the cage, for 
a total recovery of 80.5%. The sucralose recovered was primarily unchanged in both 
groups, with unidentifiable small amounts of more polar conjugates present. 
2.3.1.5 Summary of Animal Models 
Overall, animal models including mice, rats, dogs, and rabbits demonstrate that 
most orally administered sucralose is not absorbed into plasma and is excreted in the 
feces, and nearly all of the recovered sucralose is unchanged. No differences were 
found between naïve and chronic consumers, and the amount of sucralose in the dose 
does not significantly alter the percentages of total or route of excretion. 
2.3.2 Human Models 
A similar study design to those presented above in animal models was used to 
determine the pharmacokinetics of sucralose in man at two separate doses (Roberts et 
al., 2000). Eight healthy males aged 30-48 received a solution of 1 mg/kg of sucralose 
that contained 14C-sucralose, and two of these subjects were chosen to receive 10 
mg/kg sucralose in a similar follow-up study. After 5 days, the participants receiving the 
dose of 1 mg/kg excreted 14.5% in the urine and 78.3% in the feces, for a total recovery 
of 92.8%; the participants receiving the 10 mg/kg dose excreted 11.2% in the urine and 
85.5% in the feces, for a total recovery of 96.7%. The sucralose found was primarily 
unchanged, with two more polar glucuronide conjugates found as 2.6% and 1.6-1.9% of 
the total dose in the 1 mg/kg and 10 mg/kg groups, respectively. Following the 1 mg/kg 
dose, the average peak concentration was 262 ng equivalents per mL and occurred 
about 2 hours after consumption. After 12 hours the concentration dropped to 36 ng 
equivalents per mL, and very slowly declined for the remainder of the study. This human 
12 
 
model demonstrates that, similar to animal models, most sucralose is unabsorbed and 
excreted through the feces, while the amount that is absorbed passes through the body 
primarily unchanged. 
As I am aware of only one published ADME study in humans, which included 
only 8 subjects (Roberts et al., 2000), more research should be included in this area to 
confirm the findings presented here. Furthermore, each of these eight subjects were 
healthy males, which excludes a large portion of the population, including females and 
people with metabolic dysregulation, such as obesity or type 2 diabetes. 
2.3.2.1 Metabolic Responses to Sucralose: Human Clinical Trials 
Studies investigating the metabolic responses of sucralose typically measure 
fasting or postprandial parameters related to plasma glucose control, such as the 
insulinemic and incretin responses, C-peptide, HbA1C, and gastrointestinal peptides. 
These studies can be separated into either acute or chronic exposure to sucralose, as 
well as the population studied (healthy subjects or subjects with diabetes). 
2.3.2.1.1 Chronic Consumption 
2.3.2.1.1.1 Healthy Subjects 
Two studies investigating repeated exposure to sucralose were conducted by 
Baird et al. 2000 (Baird et al., 2000). In one of these studies, eight  subjects (mean 
weight: 70kg) received ascending doses of sucralose (up to 10 mg/kg) in a solution 
every other day for 10 days, followed by daily doses of 2 mg/kg (3 days) and 5 mg/kg (4 
days). The results showed that sucralose consumption did not affect blood 
concentrations of glucose or insulin measured after an overnight fast. Additionally, a 
50g oral sucrose tolerance test was performed a week after the final sucralose dose, 
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which showed a normal postprandial insulin response. Blood sucralose measurements 
were taken following the 10 mg/kg dose, which showed a peak concentration around 1 
hour, which decreased afterwards until it was barely detectable after 24 hours. In the 
second study from this group, 108 participants were divided into two groups receiving 
either a sucralose (47 males, mean weight: 79 ± 11 kg; 30 females, mean weight: 60 ± 
7 kg ) or fructose (50 g/day) (17 males, mean weight: 73 ± 9 kg; 14 females, mean 
weight: 65 ± 7 kg) solution for 12 weeks. The group receiving sucralose had doses of 
125 mg/day for weeks 1-3, 250 mg/day for weeks 4-7, and 500 mg/day for weeks 8-12. 
These doses of sucralose ranged between 4.8 to 8.0 mg/kg/day for males and 6.4 to 
10.1 mg/kg/day for females, nearly all above the FDA ADI for sucralose. The 
researchers did not find any changes to fasting blood insulin or glucose between groups 
or within groups from the beginning to end of the study. One week after the last dose of 
sucralose, glucose and insulin responses to a 50 g sucrose load were similar between 
groups. There was also no accumulation of sucralose in the blood during prolonged 
daily exposure. 
In another study investigating the effects of high doses of sucralose consumption 
per day, 48 males received either 1000 mg/day of sucralose or a cellulose placebo, both 
administered as capsules for 12 weeks (Binns, 2003). This amount of sucralose 
averaged 13.22 mg/kg/day across participants, well above the 5 mg/kg FDA ADI. 
Results from weekly blood samples showed that there was no affect throughout the 





2.3.2.1.1.2 Subjects with Type 2 Diabetes 
One hundred and twenty eight subjects with type II diabetes were investigated in 
a double-blind, placebo-controlled, randomized trial with daily dosing of sucralose for 13 
weeks (Grotz et al., 2003). Subjects were separated into groups receiving sucralose 
(667 mg/day) (n = 67) or cellulose (n = 69) administered in capsules. This amount of 
sucralose was approximately 7.5 mg/kg/day, 50% more than the FDA ADI. Following 
the 13 weeks, all subjects received the cellulose capsules for 4 weeks. Blood samples 
were taken every two weeks to measure fasting plasma glucose, serum C-peptide, and 
HbA1c. The results showed no differences between any of the parameters measured 
throughout the 13-week trial. At the end of the 4-week follow-up with cellulose capsules, 
fasting plasma glucose was significantly lower in the sucralose group compared to 
baseline and to the cellulose group. 
2.3.2.1.1.3 Summary of Chronic Consumption 
Together, the results from these four studies show that consumption of sucralose 
up to 13 weeks, at concentrations in various ranges both within and above the FDA ADI, 
does not have any measurable alterations to biochemical measurements, specifically in 
regards to maintaining glucose homeostasis, in healthy subjects or subjects with 
diabetes. However, this data is in contradiction with findings from epidemiological 
studies, which indicate that chronic NNS consumption is associated with weight gain, 
type 2 diabetes, and metabolic syndrome (reviewed by Swithers, 2013). 
It is important to note that many of the doses used in the aforementioned studies 
were much higher than the estimated daily intake values from the previous section, 
which, in fact, may be a limitation as opposed to a strength. It has been shown that at 
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high concentrations, some NNS, such as saccharine and acesulfame potassium (Ace-
K), become antagonists to the sweet taste receptor and are perceived as more bitter 
than sweet (Galindo-Cuspinera et al., 2006). The suppression of sweet taste perception, 
along with bypassing the oral cavity by using capsules, does not provide study designs 
capable of determining the role that matching sweet taste with caloric value has on 
metabolic regulation. Swithers and Davidson have demonstrated that rats exposed to 
sweet tastes without a caloric value (consuming NNS) consumed more calories, 
expended less calories, and increased their adiposity and body weight (Swithers and 
Davidson, 2008). The reasoning behind this may be that animals predict the caloric 
value of food based on the accompanying taste perception, in this case sweetness. 
When this predictive relationship is no longer valid, it may diminish physiological 
responses responsible for regulating energy homeostasis. 
Furthermore, in regards to the interaction between sucralose and the sweet taste 
receptor, using capsules as a route of administration for sucralose consumption does 
not mimic consumer use. It is not clear where the capsules dissolve and release 
sucralose, so it is unknown which post-oral sweet taste receptors may have also been 
bypassed. It is important for future studies investigating sucralose chronic consumption 
to make sure that the sucralose administered is perceived as sweet by the mouth and is 







2.3.2.1.2 Acute Consumption 
2.3.2.1.2.1 Healthy Subjects 
2.3.2.1.2.1.1 Intragastric Infusion of Sucralose Alone: Bypassing the Oral Cavity 
The studies included here include participants who acutely received sucralose 
alone through intragastric infusions, therefore eliminating the potential for cephalic 
phase responses related to the sweet taste of sucralose in the mouth. 
Ma et al. administered four treatments of saline, 50 g sucrose, 80 mg sucralose, 
and 800 mg sucralose to seven normal-weight subjects (BMI: 21.6 ± 1.2 kg/m2) on 
separate testing days in a randomized, single-blinded crossover study (Ma et al., 2009). 
Blood samples were taken at the time of infusion and up to 4 hours following to 
measure blood glucose, plasma insulin, GLP-1 and GIP. The results demonstrate that 
neither concentration of sucralose had effects different from the water treatment, 
whereas blood glucose, plasma insulin, GLP-1 and GIP all increased following the 
sucrose treatment. 
In the other study utilizing administration through intragastric infusion, 6 males 
and 6 females, all normal-weight (BMI: 23.0 kg/m2), received 6 different treatments 
(water, 169 mg aspartame, 220 mg Ace-K, 62 mg sucralose, 25 g fructose, and 50 g 
glucose) to investigate both NNS and caloric sweeteners (Steinert et al., 2011). Blood 
samples were taken at infusion and up to 2 hours afterwards to measure blood glucose, 
insulin, and glucagon and plasma GLP-1, peptide tyrosine tyrosine (PYY), and ghrelin. 





2.3.2.1.2.1.2 Sucralose Consumption Alone 
Studies included here will administered sucralose without the addition of 
substantial calories to fasted normal-weight subjects. Seven females and one male 
participated in a randomized, single-blinded, crossover design (Ford et al., 2011). 
Subjects consumed or were sham-fed 41.5 mg of sucralose on two separate testing 
occasions. Neither condition elicited altered responses in plasma glucose, insulin, GLP-
1, or PYY, nor measurements of appetite compared to a water control. 
Six men and ten women, all without obesity, participated in a randomized, 
crossover, double-blind study receiving three different strawberry jams on separate 
testing days (Ibero-Baraibar et al., 2014). The jams were 60 g, one sweetened with 
naturally occurring sugars (25 g) and two with sucralose (15 and 17 mg). The results 
showed that jams containing sucralose did not raise blood glucose or insulin 
concentrations above baseline, while the sugar containing jams increased both. 
Additionally, we have systematically reviewed and conducted a meta-analysis on 
the effects of all NNS consumption without calories, including sucralose, on 
measurements of fasting blood glucose (Nichol et al., 2018). The overall results 
indicated that sucralose consumption did not alter fasting glycemic concentrations at 
any measured time point. Overall, the data strongly suggest that acute exposure to 
sucralose without a substantial caloric load does not affect parameters related to 





2.3.2.1.2.1.3 Intraduodenal Infusion of Sucralose with a Caloric Load: Bypassing the 
Oral Cavity 
To the best of my knowledge, only a single study has utilized intraduodenal 
infusion as a vehicle of administration for sucralose and the preceding caloric load (Ma et 
al., 2010). Eight males and two females, all normal-weight (BMI: 23.4 ± 0.8 kg/m2), 
received a total of 960 mg sucralose, or a saline control, by continuous fusion over 150 
minutes. 30 minutes into the infusion, glucose and 3-O-methyl glucose (3-OMG) were 
infused at a rate of 1 calorie/min for the next 2 hours. Blood samples were taken for the 
entirety of the 150-minute infusion to measure blood glucose, GLP-1, and 3-OMG. For 
the 30 minutes prior to the caloric load, sucralose did not affect baseline measurements 
of blood glucose or GLP-1. Following the caloric load, the sucralose and saline 
treatments had similar increases to blood glucose, GLP-1, and 3-OMG concentrations. 
2.3.2.1.2.1.4 Sucralose Consumption with a Caloric Load 
The studies included here evaluated the effect that sucralose consumption has 
on postprandial glucose regulation following a caloric load in healthy subjects. Twenty 
two healthy subjects (BMI: 25.6 ± 4.6 kg/m2) consumed either diet soda (sweetened 
with sucralose and Ace-K) or unflavored carbonated water ten minutes prior to an 
OGTT (Brown et al., 2009). The results showed that postprandial glucose and 
insulinemic responses were unchanged between the two treatments. However, the 
GLP-1 area under the curve (AUC) and peak were significantly greater after diet soda 
consumption compared to the carbonated water. 
Eight healthy females (BMI: 22.2 ± 1.7 kg/m2) took part in a randomized cross-
over study with pre-load treatments of 6 g of Splenda (which contained ~72 mg of 
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sucralose and ~5.928 g of glucose and maltodextrin combined), 6 g Splenda in 
combination with 50 g sucrose, 50 g sucrose, or water (Brown et al., 2011). Each 
participant consumed the four treatments on separate testing days, with a breakfast of 
scrambled eggs, cheese, orange juice, and buttered toast given an hour after the 
treatment. Blood samples were taken at fasting, for an hour after the pre-load treatment, 
and for 2 hours following the breakfast consumption to measure blood glucose, insulin, 
glucagon, triglycerides, and ghrelin. Splenda consumption alone did not cause 
differences in any measured parameters compared to the water treatment at fasting (0-
1 hours after pre-load) or post-prandial (0-2 hours after the breakfast meal) times. 
Additionally, Splenda consumption in combination with sucrose was no different from 
sucrose in any measured parameters after pre-load or breakfast consumption. 
Ten healthy males (BMI: 25.5 ± 1.0 kg/m2) received four different pre-load 
treatments as part of a randomized, single-blinded crossover study on four separate 
testing days (Wu et al., 2013). The treatments were water, 52 mg sucralose, 200 mg 
Ace-K, and 46 mg sucralose in combination with 26 mg Ace-K, which were all 
consumed 10 minutes prior to a 75 g OGTT. Blood samples were taken prior to the pre-
load and up to four hours after the OGTT to measure blood glucose, insulin, and GLP-1. 
The results showed that none of the sweetener treatments were different from water in 
terms of any of the parameters measured. 
In a randomized, single-blinded crossover trial, eight subjects (four male, four 
female) with an average BMI of 30.3 ± 4.5 kg/m2  were administered 3 pre-load 
treatments (200 mL water, 24 mg sucralose in solution, or 72 mg aspartame in solution) 
15 minutes prior to a 75 g OGTT (Temizkan et al., 2015). Blood samples were taken 
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prior to pre-load ingestion and up to two hours after the OGTT to measure blood 
glucose, insulin, C-peptide, and GLP-1. The results indicated that on the day of 
sucralose consumption, blood glucose concentrations peaked 15-30 minutes earlier, 
blood glucose AUC was lower, and the GLP-1 AUC was greater compared to water. 
Insulin and C-peptide concentrations and AUCs were similar between the sucralose and 
water conditions. 
Ten healthy subjects (seven males, three females; BMI: 25.5 ± 1.5 kg/m2) 
participated in a single-blind, randomized crossover trial testing the effects of four pre-
load treatments on post-prandial glycemia and gastric emptying (Wu et al., 2011). The 
treatments consisted of 60 mg sucralose, 40 g glucose, 40 g 3-OMG, or 40 g 
tagatose/isomalt mixture (TIM), which were consumed 15 minutes prior to a meal 
containing potatoes, glucose, and egg yolk. Blood samples were taken before the pre-
load and up to four hours post-meal ingestion to measure blood glucose, serum insulin, 
plasma GLP-1 and GIP. Sucralose and TIM did not affect any of the parameters for the 
15 minutes between the pre-load and meal, while glucose increased all measurements 
and 3-OMG increased only plasma GLP-1 and GIP. Following the meal, blood glucose, 
was significantly lower on the day of sucralose and TIM consumption compared to 
glucose, and sucralose was significantly lower than 3-OMG. Postprandial serum insulin 
incremental AUC (iAUC) was greater following the glucose pre-load compared to all 
others. Plasma GLP-1 was significantly lower on the day of sucralose consumption 
compared to all other pre-loads following the meal. Postprandial plasma GIP was 
significantly lower for both the sucralose and TIM pre-loads compared with glucose and 
3-OMG.This study did lack a water control to better evaluate the effects of sucralose on 
21 
 
the measured metabolic responses, but the results presented here show differences 
between sucralose and caloric sweeteners. 
Sylvetsky et al. designed a randomized crossover study to determine the effects 
of sucralose consumed in water (study arm 1, n = 30, BMI: 25.8  4.2 kg/m2 and 
consumption of sucralose-containing sodas (study arm 2, n = 31, BMI: 26.3  7.5 kg/m2) 
10 minutes prior to a 75 g OGTT (Sylvetsky et al., 2016). Blood samples in both study 
arms were taken prior to the pre-load consumption and up to 2 hours following the 
OGTT to measure blood glucose, insulin, C-peptide, GLP-1, and 3-OMG. Both study 
arms also had subjects come on four separate testing days to receive the treatments. In 
study arm 1, the 4 pre-load treatments contained water, 68 mg sucralose, 170 mg 
sucralose, and 250 mg sucralose. The results showed that none of the concentrations 
of sucralose were different from water in regards to any of the measured parameters. In 
study arm 2, the 4 pre-load treatments were carbonated water, diet cola (68 mg 
sucralose, 41 mg Ace-K, and other ingredients), diet lemon-lime soda (18 mg sucralose, 
18 mg Ace-K, 57 mg aspartame, and other ingredients), and carbonated water (68 mg 
sucralose and 41 mg Ace-K). The results showed that the carbonated water sweetened 
with sucralose and Ace-K was no different from the plain carbonated water in any of the 
measured parameters. Each of the three treatments containing NNS increased insulin 
AUC by 22-25% compared to the water control, but did not reach statistical significance. 
Diet cola did demonstrate a higher GLP-1 AUC compared to carbonated water, which 
indicates that this may have been due to other ingredients found in the soda aside from 
the artificial sweeteners. Whether the rise in GLP-1 AUC is due to the other ingredients 
alone, or an interaction between certain ingredients and the NNS, was not determined. 
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Pepino and collaborators performed a randomized crossover study in people with 
obesity (BMI: 41.0  1.5 kg/m2) who were considered healthy (not diagnosed with 
diabetes and a homeostatic model assessment for insulin resistance (HOMA-IR) < 2.6) 
and were non-regular consumers of NNS (Pepino et al., 2013). Subjects (15 females 
and two males) ingested pre-load treatments of water or 68 mg sucralose ten minutes 
prior to a 75 g OGTT on two separate testing days. Blood samples were taken prior to 
the pre-load treatments and up to 5 hours following the OGTT to measure plasma 
glucose, insulin, C-peptide, glucagon, GLP-1 and GIP. They found that concentrations 
of glucose, insulin, and C-peptide in plasma reached higher peaks and insulin AUC was 
greater on the day of sucralose consumption compared to water. 
2.3.2.1.2.2 Subjects with Diabetes 
2.3.2.1.2.2.1 Sucralose Consumption with a Caloric Load 
A follow-up study was conducted based on the findings from Brown et al. 2009 
(Brown et al., 2012). Using a similar study design (as previously mentioned), subjects 
included in this study were diagnosed with type 1 (n = 9, BMI: 21.7  2.4 kg/m2) or type 
2 (n = 10, 35.0  6.8 kg/m2) diabetes. The authors did not indicate whether subjects with 
type 1 diabetes continued their ongoing insulin treatment during the study. The results 
in these participants showed that subjects with type 1 diabetes had an increase in GLP-
1 AUC following ingestion of diet soda compared to carbonated water that was similar to 
that observed in their previous study in healthy subjects. However, the consumption of 




A second subject pool including people with type 2 diabetes was included in the 
study conducted by Temizkan et al. (Temizkan et al., 2015). Four males and four 
females (BMI: 33.7  5.4 kg/m2) participated in the study, following the aforementioned 
design. The results here indicated that blood glucose, insulin, C-peptide, and GLP-1 
AUCs were not different between the sucralose and water treatments. 
In a randomized, double-blind crossover study, subjects with type 1 diabetes 
(eight males, five females, BMI: 32.0  1.9 kg/m2) and type 2 diabetes (eight males, five 
females, BMI: 23.7  0.9 kg/m2) ingested, by capsules, both a cellulose control and 
1000 mg sucralose on two separate testing occasions (Mezitis et al., 1996). Subjects 
with type 1 diabetes received their usual insulin or sulfonylurea dose 30 minutes before 
receiving their capsules. Immediately after consumption, participants received a liquid 
breakfast comprised of 360 calories. Blood samples were taken prior to and up to 4 
hours following any consumption to measure blood glucose and serum C-peptide. The 
results indicated that both groups showed similar results across all parameters between 
the sucralose and cellulose control treatments. 
2.3.2.1.2.3 Summary of Acute Consumption 
The studies presented here indicate that, regardless of route of administration, 
sucralose alone does not alter any measured parameters related to fasting glucose 
regulation in healthy participants. A study has yet to be conducted investigating the 
effect of acute consumption of sucralose alone including subjects with diabetes. Diet 
cola consumed prior to an OGTT caused a greater post-prandial GLP-1 AUC in non-
obese, healthy subjects (Brown et al., 2009, Sylvetsky et al., 2016) and non-obese, type 
1 diabetics (Brown et al., 2012), but not in subjects with obesity and type 2 diabetes 
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(Brown et al., 2012). The increases in GLP-1 AUC were not replicated in carbonated 
water sweetened with the same amounts of sweetener as the diet cola (Sylvetsky et al., 
2016); however, the results from Temizkan et al. demonstrate that post-prandial GLP-1 
AUC was greater after a sucralose pre-load compared to water in non-obese, healthy 
subjects, but not subjects with obesity and type 2 diabetes (Temizkan et al., 2015). 
Furthermore, the findings from Sylvetsky et al. and our group (Pepino et al., 2013) 
suggest that a pre-load of sucralose (in diet soda or in water alone) increases post-
prandial plasma insulin AUC in non-diabetic normal-weight subjects and subjects with 
obesity. 
Overall, the data summarized here on the effects that sucralose consumption 
may have on post-prandial glucose regulation is discrepant. It is unclear whether 
differing results are due to being normal-weight vs. obese or insulin sensitive vs. 
resistant. Increases in post-prandial GLP-1 AUC were observed in non-obese, insulin 
sensitive subjects (Brown et al., 2009, Sylvetsky et al., 2016, Temizkan et al., 2015), but 
not insulin sensitive subjects with obesity (Pepino et al., 2013) or subjects with obesity 
and type 2 diabetes (Brown et al., 2012, Temizkan et al., 2015). Post-prandial plasma 
insulin AUC was increased in both insulin sensitive normal-weight subjects (Sylvetsky et 
al., 2016) and insulin sensitive subjects with obesity (Pepino et al., 2013). Nonetheless, 
a majority of the studies presented in this review found no effect of sucralose 
consumption on any parameters related to post-prandial glucose control in normal-
weight subjects. 
Based on the overall review of the literature, we are interested in the effects that 
sucralose has on post-prandial glycemic control in people with obesity who are insulin 
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sensitive. People with obesity are of particular interest because there are fewer studies 
including this population, more people with obesity use NNS compared to their normal-
weight counterparts (36% vs 22%, respectively) (Sylvetsky et al., 2012), and data from 
animal models suggest that subjects with obesity may be most vulnerable to the effects 
of NNS consumption (Swithers et al., 2013). Additionally, we believe it is important to 
control for prior NNS use because of data from animal models suggesting chronic NNS 
use is associated with increases in active (Margolskee et al., 2007, Moran et al., 2010, 
Stearns et al., 2010) and passive glucose absorption (Mace et al., 2007). Therefore, we 
would expect frequent users to have greater glycemic responses to a glucose load than 
non-users, and would have a blunted response to a sucralose pre-load (experimental 
condition) due to the similarities between the experimental condition and control 
condition (water pre-load) in this population. Correspondingly, our current study was 
designed to investigate the impact of sucralose consumption, and of its sweet taste 
alone, on post-prandial glucose regulation in both normal-weight subjects and subjects 




CHAPTER 3: RESEARCH DESIGN AND METHODS 
 
3.1       Subjects 
 Thirty-eight potential participants (16 normal-weight subjects and 22 subjects 
with obesity) enrolled in the study and completed a screening visit that included a 2 hour 
OGTT as part of a comprehensive medical evaluation, and a detailed questionnaire 
used in previous studies that inquired about typical NNS use (Klein et al., 2006, Pepino 
et al., 2013). Subjects with a fasting plasma glucose concentration ≥ 7 mmol/L, a 2-hour 
post glucose load plasma glucose concentration ≥ 11.1 mmol/L, or significant insulin 
resistance based on a HOMA-IR score > 3, were excluded from participation. Also, 
those who were regular consumers of NNS (i.e., reported consuming more than one 
diet beverage per week, one spoonful of NNS per week, or an equivalent amount of 
NNS in foods); smoked tobacco cigarettes in the past six months; were pregnant or 
breastfeeding; had a history of malabsorptive syndromes, bariatric surgery, or 
inflammatory intestinal disease; or were taking any medication which may affect glucose 
metabolism were excluded. Out of 38 subjects, 14 failed screening, 3 were lost to 
follow-up after their screening visit, and 2 did not complete one of the study visits 
(Figure 1). Data are therefore presented for the 9 subjects with obesity and 10 normal-
weight subjects who completed the study (Table 1). This study was approved by the 
institutional review board at Washington University School of Medicine in St. Louis, and 
all screened subjects gave informed written consent before participation. 
 Subjects were evaluated on three study visits separated by ~ 1 week with a 




Figure 1. Subject Recruitment Flowchart 
 
Flowchart showing the number of participants screened for eligibility, the amount excluded in each group, 
and the amount lost to follow up. The bottom two boxes show that we had ten normal-weight subjects and 





Table 1. Subject Characteristics 
 
Data are mean (SD), with the exception of race data which are n (%) 




morning to the Clinical Research Unit at Washington University School of Medicine at 
0700 h. Subjects were instructed to fast overnight (12 hours) at home and to avoid 
physical exercise for 3 days before each study visit. After obtaining vital signs, one 
catheter was inserted into a forearm vein for infusion, and a second catheter was 
inserted into a radial artery to obtain blood samples. A primed, continuous infusion of 
[6,6-2H2] glucose (priming dose, 22 µmol/kg; infusion rate of 0.22 µmol/kg*min) was 
started and maintained until the end of the study. After 3.5 hours of tracer infusion, 
subjects ingested a 75 g OGTT that included 1.5 g of [U-13C6] glucose.  Blood samples 
were obtained at 40, 30, 20, 10, 8, 6, 4, and 2 minutes before and at 0, 10, 20, 30, 40, 
50, 60 minutes after ingestion of glucose. Following 1-hour post-ingestion, blood 
samples were taken every 20 minutes for four hours to determine glucose kinetics and 
plasma hormone and sucralose concentrations. In a randomized order, subjects drank 
60 mL of 2 mmol/L sucralose (i.e., 48 mg sucralose) (sucralose ingestion condition) or 
an equivalent volume of distilled water (water condition), or tasted the same 
concentration of sucralose and expectorated (sucralose sham-fed condition) 10 minutes 
prior to glucose ingestion. 
3.2    Rationale for Dose of Sucralose Chosen 
The dose of sucralose was chosen to replicate the amount used in the previous 
study (Pepino et al., 2013). The logic underlying the selection of this sucralose 
concentration is that 2 mmol/L of sucralose effectively stimulated incretin release in 
human intestinal cells in vitro (Jang et al., 2007), and 48 mg closely matches the total 
amount of sucralose present in 8-ounces of diet soda if it was sweetened exclusively 
with sucralose (Sucralose, 2017). 
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3.3   Rationale For Choice of Primary Metabolic Outcomes 
Pepino and collaborators have shown that the acute ingestion of sucralose 
increases peak plasma glucose, plasma C-peptide and insulin concentrations, and 
insulin AUC after an OGTT, while there was a trend for GIP concentrations to be 
elevated (Pepino et al., 2013). Therefore, insulin was selected because 1) it is a primary 
regulatory hormone for plasma glucose concentrations and 2) we are interested in 
determining if the results previously reported are replicable in people with obesity and 
generalizable to normal-weight people. C-peptide is also an important outcome because 
it is secreted in equimolar amounts to insulin and is not metabolized by the liver. Unlike 
insulin, which undergoes a substantial and variable amount of hepatic extraction during 
first pass metabolism (Polonsky and Rubenstein, 1984), C-peptide is removed from 
circulation, by renal uptake and filtration, at a more constant rate which is preserved 
during fasting and post-prandial conditions (Licinio-Paixao et al., 1986). Therefore, 
changes to C-peptide concentrations better represent changes to insulin secretion than 
insulin concentrations alone because changes to insulin concentrations can be largely 
due to the variability of hepatic extraction. GIP was selected as an outcome variable 
because there was a trend for sucralose to increase concentrations after an OGTT, 
which suggests that GIP, an incretin, may have contributed to the increase in glucose-
stimulated insulin secretion. Additionally, we measured for plasma sucralose 
concentrations to see if different metabolic responses to sucralose between people with 
obesity and normal-weight people were due to different amounts of sucralose absorbed 




3.4   Biochemical Measurements 
At all time-points, plasma glucose was measured immediately after collection by 
using an automated glucose analyzer (YSI 2300 STAT plus; Yellow Springs 
Instruments, Yellow Spring, OH). Blood samples were also collected in chilled EDTA 
tubes containing a protease inhibitor cocktail (Millipore, Billerica, MA). These samples 
were placed on ice and centrifuged at 4oC and the plasma was stored at -80oC for 
subsequent analyses. Plasma insulin and C-peptide concentrations were measured at 
the same time-points as plasma glucose up to 60 minutes post-glucose ingestion. 
Following the 60-minute post-ingestion, they were measured every 40 minutes until the 
end of the test. Plasma insulin concentrations were determined by using a two-site 
immunoenzymatic assay (DxI 800; Beckman Instruments, Chaska, MN), and C-peptide 
by using a solid-phase two-site chemiluminescent immunometric assay (Siemens 
Medical Solutions Diagnostics, Los Angeles, CA). Plasma GIP was measured at 10 and 
2 minutes before and at 0, 10, 30, 50, 60, 100, 140, and 180 minutes after glucose 
consumption by using commercially available immunoassay kits from Millipore (Billerica, 
MA). The glucose tracer-to-tracee ratio in plasma was determined using gas 
chromatography-mass spectrometry (Hewlett-Packard MSD 5973 system with a 
capillary column) after derivatizing glucose with acetic anhydride. 
Plasma sucralose concentrations were measured right before and at 10, 40, 70, 
130, 190, and 310 minutes after sucralose consumption by using liquid 
chromatography-mass spectrometry (Sylvetsky et al., 2017a). Sucralose was first 
extracted from plasma by vortexing a 50 µL aliquot of plasma and 500 µL methanol 
containing D6-sucralose internal standard for 5 minutes. The tube was then centrifuged 
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at 14,000 RPM (revolutions per minute) for 10 minutes. Supernatant (300 µL) was 
transferred to a high-performance liquid chromatography (HPLC) vial and sealed. 
Assays were performed with an Acquity I-Class UPLC (Waters Corp., Milford MA, USA) 
and an Acquity UPLC BEH C-18 column (2.1 mm x 50 mm, 1.7 µm) coupled with a Q-
Exactive MS (Thermo Scientific, Waltham, MA, USA) with an HESI-II electrospray 
source. The relative standard deviation across all samples and replicates was < 4%. 
3.5   Calculations 
The AUCs and iAUCs were calculated using the trapezoid method (Allison et al., 
1995). HOMA-IR values were calculated using the HOMA2 calculator (available from 
www.OCDEM.ox.ac.uk). Total glucose rate of appearance (total Ra) was calculated 
using Steele’s equation for non-steady state conditions (Steele, 1959). Oral rate of 
glucose appearance (oral Ra), endogenous glucose production (EGP), and rate of 
glucose disappearance (Rd) were calculated as previously described (Gastaldelli et al., 
2007). For glucose kinetics statistical analyses, we included data collected between 0 
and 180 minutes post glucose ingestion, instead of 0 and 300 minutes, due to 
cumulative errors in the model beyond 180 minutes.  
3.6   Statistical Analyses 
Differences between groups for demographics, measurements of fasting 
outcome variables, plasma sucralose peak, time to peak, and iAUC were determined 
using an unpaired t-test. To determine whether plasma sucralose concentrations were 
higher in subjects with obesity than in normal-weight subjects, we used a repeated 
measure ANOVA with time as a within factor and group as a between factor. We did not 
have data on plasma sucralose concentrations from one subject with obesity, so 
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assessments conducted for this outcome variable include eight subjects with obesity 
and ten normal-weight subjects. 
The statistical significance of the effect of tasting and ingesting sucralose (or just 
tasting sucralose) on plasma glucose, insulin, C-peptide, and GIP concentrations, as 
well as glucose kinetics (total glucose Ra, oral glucose Ra, EGP, and glucose Rd), 
during the OGTT in normal-weight subjects and subjects with obesity was determined 
by conducting separate repeated ANOVAs for each group and each outcome variable 
including condition (water, sucralose-ingestion, and sucralose sham-fed) and time-point 
as within-subject factors. For the same outcome variables, repeated measures ANOVAs 
were also conducted for the AUCs, iAUCs, and incremental peaks with condition (water, 
sucralose-ingestion, and sucralose sham-fed) as within subject factor. If the sphericity 
assumption of the analysis of variance was violated, the Huynd-Feldt correction was 
used. When ANOVAs revealed significant effects, post-hoc Fisher Least Significant 
Difference analyses were conducted. Based on data from our previous study in subjects 
with obesity (Pepino et al., 2013), we tested the a priori hypothesis that the iAUC of 
insulin was greater after sucralose ingestion than after the water control using planned 
comparisons in each group. Data in the tables and figures are presented as means and 
standard errors of the mean (SEM), unless otherwise stated. All analyses were 
performed with STATISTICA 13.2 (TIBCO Software Inc., Palo Alto, CA) and criterion for 
statistical significance was p ≤ 0.05. 
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CHAPTER 4: RESULTS 
 
4.1   Subject Characteristics and Plasma Sucralose Concentrations 
There were no significant differences in age, sex, and race distribution between 
groups (Table 1). Although fasting plasma glucose concentrations were not significantly 
different between groups (t(17) = -0.69, p = 0.50), fasting plasma insulin concentrations 
(t(17) = -3.30, p = 0.004) and HOMA-IR (t(17) = -4.38, p < 0.001) were significantly higher 
in the group with obesity than in the normal weight group (Table 1). The shape of the 
plasma sucralose concentration versus time curve tended to be different between 
groups (F(2,30) = 3.14, p = 0.06), with higher sucralose concentrations during the last 
hour of the test in subjects with obesity than in normal-weight subjects (Figure 2). 
However, peak sucralose concentrations, the time to reach peak sucralose 
concentration, and plasma sucralose iAUCs were not significantly different between 
groups (all p-values > 0.19; Table 2). 
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Figure 2. Plasma Sucralose Concentrations 
 
Mean plasma sucralose concentrations in normal-weight subjects and subjects with obesity following 




Table 2. Hormonal Responses, Glucose Kinetics, and Plasma Sucralose 
 
 
Data are mean ± SEM for nine subjects with obesity and ten normal-weight subjects. 
* indicates a significant difference from water control (p < 0.05) 









4.2   Plasma Glucose and Hormone Concentrations Within Groups 
In the normal-weight group, neither sucralose ingestion nor sucralose sham-fed 
conditions were different from water in regards to mean plasma concentrations, iAUCs, 
and incremental peaks for glucose, C-peptide, and GIP (Table 2, Figure 3, Figure 4). 
However, there was a trend for the average plasma insulin concentrations over time to 
be lower on the sucralose ingestion and sucralose sham-fed conditions compared to 
water (F(2,18) = 2.73, p = 0.09; Figure 3). 
In the group with obesity, sucralose ingestion increased the plasma glucose 
iAUC by 34 ± 12 % compared to water, but the differences between conditions did not 
reach statistical significance (F(2,14) = 3.66, p = 0.06; Table 2, Figure 4). There were no 
differences to mean or incremental peak plasma glucose concentrations between 
conditions (Table 2, Figure 3). Compared to the water and sucralose ingestion 
conditions, sucralose sham-fed decreased plasma insulin concentrations within the first 
hour of the OGTT in the group with obesity (F(9,72) = 2.01, p = 0.05; Figure 3). Similarly, 
sucralose-sham fed decreased C-peptide concentrations compared to the water and 
sucralose ingestion conditions from 50 to 60 minutes (F(13,105) = 2.23, p = 0.01; Figure 
3). Compared to water, sucralose ingestion increased C-peptide iAUC by 22 ± 10%  
(F(2,16) = 3.85, p < 0.05; Fisher LSD p < 0.02) and insulin iAUC by 16 ± 9%, although for 
insulin iAUC, the difference between conditions only tended to approach statistical 
significance (F(1,8) = 3.67, p = 0.09) (Table 2, Figure 4). In the group with obesity, the 
same seven out of nine subjects had greater insulin and C-peptide iAUCs after 
sucralose consumption than after water consumption (Figure 5). There were no 
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significant differences for GIP mean concentrations, iAUCs, or incremental peaks 
between conditions within the group with obesity (Table 2, Figure 3, Figure 4). 
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Figure 3.  
 
Data are mean ± SEM for plasma glucose, insulin, C-peptide, and glucagon concentrations in ten normal-
weight subjects and nine subjects with obesity after consuming water or sucralose, or being sham-fed 
sucralose, 10 minutes prior to an OGTT (given at time 0). * indicates a significant difference between 
sucralose ingestion and water, † indicates a significant difference between sucralose sham-fed and 





Data are the mean ± SEM of the incremental area under the curves for glucose, insulin, C-peptide, and 
GIP in ten normal-weight subjects and nine subjects with obesity after consuming water or sucralose, or 
being sham-fed sucralose, 10 minutes prior to an OGTT. * indicates a significant difference between 
water and sucralose ingestion conditions (p < 0.05). # indicates a trend towards a difference between 
water and sucralose ingestion conditions (p < 0.10). 
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Figure 5.  
 
Percent changes to glucose, insulin, and C-peptide iAUCs between water and sucralose ingestion 
conditions in ten normal-weight subjects and nine subjects with obesity. Bars above the 0 line indicate 
that there was a positive change between conditions.   
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4.3   Glucose Kinetics 
There were no differences to the time point curves, AUCs, or incremental peaks 
between conditions for total Ra, oral Ra, or Rd, nor the time point curves and nadirs for 
EGP, in this group (Table 2, Figure 6, Figure 7). 
Unlike that observed in normal-weight subjects, condition did affect total and 
orally derived glucose rates of systemic appearance and total glucose disappearance in 
subjects with obesity. The average total Ra across time points 0-180 min was lower 
following sucralose sham-fed than water (F(2,16) = 3.60, p = 0.05; Fisher LSD p = 0.02; 
Figure 6), and there were significant condition by time interactions for oral glucose Ra 
(F(12,95) = 1.99, p = 0.03) and for glucose Rd (F(6,51) = 2.27, p < 0.05). Post-hoc analyses 
of these interactions revealed that, compared to water, both sucralose conditions 
lowered oral Ra at 60 minutes and increased oral Ra from 120-140 minutes.  They also 
caused a lower Rd from 50-80 minutes and a higher Rd at 140 minutes, but only 
sucralose ingestion maintained the higher Rd until 160 minutes (Figure 6). There were 
no differences between conditions in regards to EGP. 
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Figure 6.  
 
Data are mean ± SEM rates of total Ra, oral Ra, EGP, and Rd in ten normal-weight subjects and nine 
subjects with obesity after consuming water or sucralose, or being sham-fed sucralose, 10 minutes prior 
to an OGTT (given at time 0). * indicates a significant difference between sucralose ingestion and water, 
† indicates a significant difference between sucralose sham-fed and water, ‡ indicates a significant 




Figure 7.  
 
Data are the mean ± SEM of the area under the curves for total glucose Ra, oral glucose Ra, and glucose 
Rd in ten normal-weight subjects and nine subjects with obesity after consuming water or sucralose, or 
being sham-fed sucralose, 10 minutes prior to an OGTT.  
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CHAPTER 5: DISCUSSION 
 
 Our results indicate that the acute ingestion of sucralose compared to water, 
prior to an OGTT, increased post-prandial plasma C-peptide concentrations and tended 
to increase post-prandial plasma insulin concentrations in people with obesity who were 
not regular consumers of NNS, but did not alter plasma C-peptide concentrations and 
tends to decrease average plasma insulin concentrations in normal-weight people. The 
group with obesity also experienced lower plasma insulin and C-peptide concentrations 
during the sucralose sham-fed condition for the first 60 minutes and from 50-60 
minutes, respectively, after the OGTT. Following sucralose consumption, plasma 
glucose iAUC during the OGTT tended to be greater compared to the water condition 
only in the group with obesity. These results suggest that both the ingestion of 
sucralose and its taste alone alter glycemic and insulinemic responses to an oral 
glucose load in people with obesity. 
 The finding that the group with obesity experienced a trend of elevated plasma 
glucose iAUC compared to water on the day of sucralose ingestion, but not the day of 
sucralose sham-fed, indicates that these changes were due to the post-ingestive effects 
of sucralose. Previous research in murine models have shown that the presence of 
sucralose in the intestine increases the rate of glucose absorption through increased 
mRNA expression (Margolskee et al., 2007) and increased translocation of GLUT2 to 
the apical membrane (Mace et al., 2007). While our data do not indicate an overall 
increase in oral Ra, our data cannot be used to estimate rates of intestinal glucose 
absorption. Because our plasma glucose measurements were taken from systemic 
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circulation, glucose appearance rates are potentially impacted by a combination of 
several processes, including 1) the fraction of ingested glucose that is emptied from the 
stomach across time; 2) the rate of glucose absorption in the intestine and 3) net 
hepatic glucose uptake when glucose passes through the liver via the portal vein. 
(Moore et al., 2012). Nonetheless, because total Ra (the sum of oral Ra and EGP) is 
unchanged, the likely cause for the increase plasma glucose iAUC was from a 
decreased rate of glucose disappearance from 50-80 minutes during the sucralose 
ingestion condition (Figure 6). These findings agree with our hypothesis of a reduced 
rate of glucose disappearance in subjects with obesity, but also reject the hypothesis 
that this would be accompanied with a lesser suppression of EGP. 
 The finding that the increased sucralose-mediated insulin response was not 
accompanied by decreased plasma glucose during the OGTT in the group with obesity 
suggests that acute sucralose consumption caused insulin resistance in these subjects. 
Also, by matching time points on the plasma insulin and glucose Rd curves, it is clear 
that similar concentrations of insulin between the water and sucralose ingestion 
conditions do not result in similar rates of glucose clearance. Following sucralose 
ingestion, rate of glucose clearance was reduced from 50-80 minutes, although insulin 
concentrations were comparable (Figure 3, Figure 6). We propose that the ingestion of 
sucralose may be potentiating the “anti-incretin effect”, which is a state of relative insulin 
resistance occurring post-prandially. 
 To better understand the “anti-incretin effect”, it is important to understand the 
“incretin effect”. First, incretins are hormones that help decrease blood glucose levels by 
promoting the secretion of insulin from the pancreas. The “incretin effect” is the 
46 
 
increased stimulation of insulin secretion after oral compared to after intravenous 
administration of glucose, both resulting in similar plasma glucose concentrations. The 
increase in insulin secretion is due to the release of the incretins GLP-1 and GIP from 
enteroendocrine L-cells and K-cells, respectively, which otherwise would not be 
released without the presence of glucose in the gastrointestinal tract. However, despite 
enhanced insulin secretion caused by the incretin effect, insulin sensitivity is lower 
during oral than intravenous glucose administration, suggesting that oral glucose 
ingestion causes a state of relative insulin-resistance, the so-called “anti-incretin effect” 
(Salinari et al., 2017).  It has been hypothesized that the “anti-incretin effect” is the state 
of relative insulin resistance reached following a meal to protect against post-prandial 
hyperinsulinemia and hypoglycemia caused by the “incretin effect”. Salinari et al. have 
provided evidence of this in their study measuring insulin sensitivity when glucose was 
given by OGTT or administered through an IV in both normal-weight people and people 
with obesity (Salinari et al., 2017). The IV glucose administration was isoglycemic to the 
OGTT, so subjects reached similar concentrations of plasma glucose during both 
treatments. Despite experiencing similar changes to glycemia, normal-weight subjects 
and subjects with obesity were 24.5% and 70.3% less insulin sensitive after oral 
consumption compared to IV administration, respectively. By utilizing the Monte Carlo 
simulation, they found that plasma insulin levels measured during the OGTT, coupled 
with insulin sensitivity values estimated during the IV administration, would result in 
severe hypoglycemia in subjects with obesity. Therefore, the authors interpreted that 
subjects with obesity are protected from hypoglycemia by becoming less insulin 
sensitive during the OGTT. In relation to our findings that suggest acute sucralose 
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consumption decreases insulin sensitivity in subjects with obesity, Salinari et al. 
demonstrated that the “anti-incretin effect” was exacerbated in their subjects with 
obesity compared to normal-weight subjects. If sucralose could amplify the relative state 
of insulin resistance of the OGTT through post-ingestive effects in the gastrointestinal 
tract, this may explain the greater amount of plasma insulin in the sucralose ingestion 
versus the sham-fed condition in the group with obesity. 
 Surprisingly, the mere perception of sucralose sweetness before drinking a 
glucose load decreased plasma insulin concentrations an hour later in the group with 
obesity, which was reciprocated in the glucose Rd curve.  Our finding that sweetness 
perception before a glucose load decreases insulin response to an OGTT complements 
well with recent findings that demonstrate that the inhibition of sweetness perception 
before a glucose load increases insulin response to an OGTT (Karimian Azari et al., 
2017). Karimian Azari and collaborators recently found that the addition of lactisole, a 
broad sweet taste receptor antagonist, to a glucose load increased plasma insulin 
concentrations during the OGTT (Karimian Azari et al., 2017). Because the lack of 
sweet taste perception in the study design of Karimian and collaborators lead to an 
increase in plasma insulin, we believe that the additional sweet taste of the sucralose 
before the OGTT in our study design caused the decline in plasma insulin in the 
sucralose sham-fed condition in the group with obesity. Because the C-peptide data 
closely matches the plasma insulin curve, we hypothesize that the decline in plasma 
insulin was due to a decreased rate of insulin secretion. However, further investigation 
into the role of sweet taste perception on post-prandial insulin secretion and clearance 
are required to determine the cause of the decline. 
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 The finding of sucralose lack of effect on any measurement of GIP in both groups 
is consistent with other studies conducted in humans which also found no effects of 
sucralose on incretin responses (Brown et al., 2011, Brown et al., 2012, Ford et al., 
2011, Ma et al., 2009, Ma et al., 2010, Pepino et al., 2013, Steinert et al., 2011, 
Sylvetsky et al., 2016, Temizkan et al., 2015, Wu et al., 2013, Wu et al., 2011), despite 
sucralose activating sweet taste receptors and stimulating incretin release in cell lines 
(Jang et al., 2007, Margolskee et al., 2007). Saltiel et al. conducted a study attempting 
to determine why results in human models are not similar to data from cell lines (Saltiel 
et al., 2017). The researchers used a rat model to either luminally administer or 
intravenously infuse the proximal small intestine with various sweeteners, including 
sucralose. They demonstrated that intra-luminal administration of 31.4 mmol/L of 
sucralose (nearly 16 times the concentration used in our study) did not elicit an incretin 
response. Additionally, intravenous administration of 10 mmol/L sucralose, but not 
1mmol/L or 0.1 mmol/L, significantly increased GLP-1 concentrations and showed a 
trend for increased GIP concentrations. The researchers suggest that the reason for the 
lack of incretin response during the luminal administration compared to the intravenous 
infusion may be due to the small amount of sucralose absorbed by rats (5-8% (Sims et 
al., 2000)). This theory fits well with our data, as we only administered 2 mmol/L 
sucralose, of which ~15% (Roberts et al., 2000) is absorbed in humans. According to 
Saltiel et al., the circulating concentration in our study (< 1 mmol/L) would not be high 
enough to elicit an incretin response. Despite this, we take caution extrapolating the 
intra-luminal administration data. The concentration used is 50 times the sweetness of a 
20% glucose sweetened solution. As mentioned previously in the literature review, 
49 
 
some artificial sweeteners become antagonists to the sweet taste receptor at high 
concentrations (Galindo-Cuspinera et al., 2006). Therefore, it is unclear whether the 
lack of incretin response was due to an antagonistic relationship with the sweet taste 
receptor in the lumen or the insufficient concentration of sucralose in circulation. Further 
investigation is still required to determine why data from in vivo studies do not replicate 
data found in vitro studies. 
 Contrary to our hypothesis, subjects with obesity and normal weight subjects 
achieved a similar peak plasma sucralose concentration after sucralose ingestion. 
However, it may still be the case that people with obesity absorb more sucralose than 
normal-weight people. Concentrations in the group with obesity continued to rise 130 
minutes following sucralose consumption, but began to decline at this same time point 
in the normal-weight group. Arguably, if groups were challenged with larger sucralose 
doses or with frequent consumption of sucralose, subjects with obesity may achieve 
higher plasma sucralose concentrations. The prolonged rise of plasma sucralose 
observed in subjects with obesity may be due to the increased permeability of the large 
intestine, which has been shown to be associated with increased visceral adiposity in 
women (Gummesson et al., 2011). In addition, plasma sucralose concentrations are 
influenced by other factors beyond intestinal absorption. A decreased rate of sucralose 
clearance, via excretion in the urine (Roberts et al., 2000), or diminished P-glycoprotein 
function in the enterocytes (Schiffman and Rother, 2013), may also explain a delayed 
decline in plasma concentrations in the group with obesity. 
 This study has some limitations. For one, our entire study population comprised 
people who do not normally consume NNS. The logic for this strict inclusion criteria was 
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based on the finding from several studies that chronic NNS ingestion upregulates the 
expression of SGLT1, which in turn increases the initial rate of Na+-dependent glucose 
uptake in three different mammalian species (mice (Margolskee et al., 2007), pigs 
(Moran et al., 2010) and cattle (Moran et al., 2014)), and increases the glycemic 
response to an oral glucose load in rodents (Suez et al., 2014, Swithers et al., 2012). 
Second, our group with obesity comprised people who had a HOMA-IR < 3, so our 
findings might not extrapolate to people with obesity who are more insulin resistant. 
Additional studies including chronic NNS users and people who are more insulin 
resistant are needed. 
In conclusion, our data suggest that acute consumption of sucralose prior to an 
OGTT augments insulin responses in people with obesity but not in normal weight 
people. These findings add to the growing evidence that sucralose is not metabolically 
inert, and is the first study, to our knowledge, to demonstrate that the sweet taste of 
sucralose alone may alter metabolic outcomes. Future studies may include a sucralose 
ingestion condition without taste (i.e., taking a pill or intragastric/intraduodenal infusion), 
prior to an OGTT, to better understand the post-ingestive effects of sucralose 
independent of the perception of its sweet taste in people with obesity. Also, 
investigating sham-feeding of other sweet-taste stimuli (caloric and non-caloric) prior to 
an OGTT could help identify if sweet taste in itself caused the changes observed in our 
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